High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial

Table 2 Participants characteristics at 24 months of follow-up by baseline BMI, Temprano study, Abidjan, March 2008–December 2012 (N = 755)

	Baseline BMI
	Underweight	Normal	Overweight	Obese	P value
	N = 75 (10.0 %)	N = 478 (63.3 %)	N = 149 (19.7 %)	N = 53 (7.0 %)	P value
Vital status at month 24 (N = 755)
Loss to follow-up	0 (0.0)	12 (2.5)	3 (2.0)	1 (1.9)	0.67
Death	5 (6.7)	5 (1.1)	2 (1.3)	1 (1.9)	0.04
Morbidity*	7 (9.3)	26 (5.4)	5 (3.4)	3 (5.7)	0.19
Endpoints (N = 597)**
At least one modification of ART***	14 (18.7)	81 (17.0)	21 (14.1)	5 (9.4)	0.42
∆CD4 (M24-M0)	225 (101–333)	231 (111–393)	231 (121–375)	214 (93–384)	0.80
VL <300 cp/ml at M24	39 (73.6)	294 (82.6)	92 (80.7)	34 (87.2)	0.33
Hemoglobin <95 g/dL at M24	3 (5.8)	15 (4.3)	2 (1.8)	1 (2.5)	0.17

Italic value are statistically significant
N number, BMI body mass index, Underweight BMI <18.5 kg/m², Normal BMI 18.5–24.9 kg/m², Overweight BMI 25–29.9 kg/m², Obese BMI >30 kg/m², P value comparisons are made using the chi square or fisher test to compare proportions or then the Wilcoxon test for median comparison
* Morbidity: any WHO stage 3 or 4 clinical event or any adverse event of grade 3 or 4 on the ANRS scale
** Endpoints for the 597 patients who completed 24 months of antiretroviral treatment
*** ART: antiretroviral therapy

ISSN: 1742-6405